SCHEMBL3592322

SCHEMBL3592322

O=C(O)NCC1CCN(Cc2ccc(-c3ccc(F)cc3)cc2Cl)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.50
CXCR4 P61073 4/20 0.49
ACHE P22303 3/20 0.48
CHRM4 P08173 1/20 0.48
HTR4 Q13639 1/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
RECQL P46063 1/20 0.46
CCR3 P51677 1/20 0.45
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
TP53 P04637 2/20 0.45
MAPT P10636 1/20 0.45
FAAH O00519 1/20 0.44
BCHE P06276 1/20 0.44
ALPL P05186 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3945562 0.89 CHRM4 (0.59) ACHECHRM4BCHE
SCHEMBL3589414 0.89 KMT2A (0.53) POLBACHECHRM4MEN1KMT2A
SCHEMBL3941799 0.80 CHRM4 (0.53) POLBACHECHRM4MEN1KMT2A
SCHEMBL3597886 0.79 CXCR4 (0.71) POLBCXCR4ALDH1A1TP53ALPL
SCHEMBL3935459 0.78 CHRM4 (0.59) ACHECHRM4ALDH1A1BCHE
SCHEMBL3592324 0.78 ACHE (0.47) ACHEMEN1KMT2AALDH1A1CYP3A4
SCHEMBL2969854 0.78 ACHE (0.42) CXCR4ACHECHRM4DRD2DRD4
SCHEMBL2773893 0.77 HSD11B1 (0.47) TP53
SCHEMBL2969849 0.76 ACHE (0.42) ACHEMEN1KMT2AALDH1A1CYP3A4
SCHEMBL2974797 0.76 CHRM4 (0.49) ACHECHRM4DRD2DRD4BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP claimed
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 POLB 2745/4885CXCR4 2384/4885ACHE 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.